Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
Bernstein maintains Eli Lilly stock Outperform, $1,100 target
Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...
FierceBiotech4h
Veru's drug conserves muscle mass for older patients taking Novo's Wegovy in phase 2 trial
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
The Four Key Pillars of Wealth Management of the Future
The role of the family office is evolving with the Great Wealth Transfer and tech advancements, among other issues. This is ...
This Wegovy user spent $5,000 on a new wardrobe after losing 80 pounds - and she's not alone
Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.
MarketWatch22h
E-Mini S&P 500 Future Continuous Contract
2-Year U.S. Treasury Note Continuous Contract $102.773 0.020 0.02% 5-Year U.S. Treasury Note Continuous Contract $106.211 0.070 0.07% 10-Year U.S. Treasury Note Continuous Contract $108.594 0.125 ...